NextCure Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

BELTSVILLE, Md., May 13, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $15.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 750,000 shares of common stock. Including the option exercise, the gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were $86.25 million. All of the shares in the offering were offered by NextCure. NextCure’s common stock is listed on The Nasdaq Global Select Market under the ticker symbol “NXTC.”

Morgan Stanley, BofA Merrill Lynch and Piper Jaffray & Co. acted as joint book-running managers of the offering.

Aregistration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission (SEC) on May 8, 2019. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by visiting EDGAR on the SEC’s website at www.sec.gov or from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, North Carolina 28255-0001, Attn: Prospectus Department, or by email at [email protected]; or Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, Minnesota, 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at [email protected].

Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
SVP, Corporate Development
(240) 762-6486
[email protected] 

Media Inquiries
Shai Biran, Ph.D.
MacDougall
(781) 235-3060
[email protected]

[ Back To TMCnet.com's Homepage ]